

Miraca and 7SBio announce strategic investment

04 July 2019 | News

Under the terms, Miraca will become a strategic investor in 7SBio, as well as use and distribute TAP products in Japan



Seventh Sense Biosystems, Inc. (7SBio), makers of TAP™, the world's first push-button blood collection device, and Miraca Holdings Inc. or Miraca (\$MRCHF), the largest commercial clinical laboratory in Japan, announced that the companies have entered into a strategic investment and distribution agreement.

Under the terms, Miraca will become a strategic investor in 7SBio, as well as use and distribute TAP products in Japan.

Dr. Robert Langer, 7SBio Co-Founder and one of 10 Institute Professors at MIT said, "We are excited to partner with the leading clinical laboratory in Japan in order to enable more patients to use TAP,"

The TAP device is positioned on a patient's upper arm, and with just a 'tap' blood is collected virtually painlessly. The intent is to enable more convenient and less expensive blood collection than traditional methods. TAP is FDA 510(k) cleared and has a CE Mark.